WO2004020375A1 - Cyclopenta[b]naphthalinderivate - Google Patents

Cyclopenta[b]naphthalinderivate Download PDF

Info

Publication number
WO2004020375A1
WO2004020375A1 PCT/EP2003/008285 EP0308285W WO2004020375A1 WO 2004020375 A1 WO2004020375 A1 WO 2004020375A1 EP 0308285 W EP0308285 W EP 0308285W WO 2004020375 A1 WO2004020375 A1 WO 2004020375A1
Authority
WO
WIPO (PCT)
Prior art keywords
independently
cyclopenta
halogen
another
hydrogen
Prior art date
Application number
PCT/EP2003/008285
Other languages
German (de)
English (en)
French (fr)
Inventor
Lars Lietzau
Matthias Bremer
Melanie Klasen-Memmer
Michael Heckmeier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10238999A external-priority patent/DE10238999A1/de
Priority claimed from DE2003124843 external-priority patent/DE10324843A1/de
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to DE50312532T priority Critical patent/DE50312532D1/de
Priority to EP03790821A priority patent/EP1532090B1/de
Priority to AU2003258538A priority patent/AU2003258538A1/en
Priority to KR1020057003174A priority patent/KR101048559B1/ko
Priority to AT03790821T priority patent/ATE461166T1/de
Priority to JP2004569707A priority patent/JP4722490B2/ja
Priority to US10/524,846 priority patent/US7291366B2/en
Publication of WO2004020375A1 publication Critical patent/WO2004020375A1/de
Priority to US11/931,711 priority patent/US7612243B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/04Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06Non-steroidal liquid crystal compounds
    • C09K19/34Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3402Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having oxygen as hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/093Preparation of halogenated hydrocarbons by replacement by halogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/25Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/35Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00Preparation of halogenated hydrocarbons
    • C07C17/35Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction
    • C07C17/354Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or of halogen atoms in the reaction by hydrogenation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C22/00Cyclic compounds containing halogen atoms bound to an acyclic carbon atom
    • C07C22/02Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings
    • C07C22/04Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings
    • C07C22/08Cyclic compounds containing halogen atoms bound to an acyclic carbon atom having unsaturation in the rings containing six-membered aromatic rings containing fluorine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/24Halogenated aromatic hydrocarbons with unsaturated side chains
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/52Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of six-membered aromatic rings being part of condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46Friedel-Crafts reactions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/64Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/04Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06Non-steroidal liquid crystal compounds
    • C09K19/32Non-steroidal liquid crystal compounds containing condensed ring systems, i.e. fused, bridged or spiro ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/14Benz[f]indenes; Hydrogenated benz[f]indenes
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/04Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06Non-steroidal liquid crystal compounds
    • C09K19/34Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3491Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having sulfur as hetero atom
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/04Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06Non-steroidal liquid crystal compounds
    • C09K19/34Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3402Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having oxygen as hetero atom
    • C09K2019/3422Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having oxygen as hetero atom the heterocyclic ring being a six-membered ring
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2323/00Functional layers of liquid crystal optical display excluding electroactive liquid crystal layer characterised by chemical composition

Definitions

  • the present invention relates to cyclopenta [b] naphthalene derivatives, their use in liquid-crystalline or mesogenic media, liquid-crystalline or mesogenic media containing these derivatives, and electro-optical display elements containing these liquid-crystalline or mesogenic media.
  • Liquid crystals have found a wide range of applications since the first commercially applicable liquid-crystalline compounds were found around 30 years ago.
  • Known fields of application are, in particular, display displays for watches and pocket calculators, and large display boards, such as are used in train stations, airports and sports arenas.
  • Other areas of application are displays of portable computers and navigation systems as well as video applications. Particularly for the latter applications, high demands are made on switching times and the contrast of the images.
  • the spatial order of the molecules in a liquid crystal means that many of its properties are directional.
  • the anisotropies in the optical, dielectric and elasto-mechanical behavior are of particular importance for use in liquid crystal displays.
  • the molecules are oriented with their longitudinal axes perpendicular or parallel to the two plates of a capacitor, it has a different capacitance; the dielectric constant ⁇ of the liquid-crystalline medium is therefore different for the two orientations.
  • dielectric positive Substances whose dielectric constant is greater when the longitudinal axes of the molecules are oriented perpendicular to the capacitor plates than when they are arranged in parallel are termed dielectric positive. Most of the liquid crystals used in conventional displays fall into this group.
  • the dipole moment oriented along the longitudinal axis of the molecule is greater than the dipole moment oriented perpendicular to the longitudinal axis of the molecule.
  • the orientation of the larger dipole moment along the longitudinal axis of the molecule also determines the orientation of the molecule in a field-free liquid crystal display.
  • TN cells derived from the English: "twisted nematic", twisted nematic
  • only about 5 to 10 ⁇ m thick liquid-crystalline layer is arranged between two flat glass plates, each with an electrically conductive, transparent layer of tin oxide or indium tin oxide as the electrode is vapor-deposited.
  • a likewise transparent orientation layer which usually consists of a plastic (eg polyimides). It serves to use surface forces to move the longitudinal axes of the neighboring crystalline molecules in a preferred direction so that they lie flat in the voltage-free state with the same orientation flat or with the same small angle of attack on the inside of the display surface.
  • a plastic eg polyimides
  • On the outside of the display are two polarizing foils, which only allow linearly polarized light to enter and exit, in a certain ano glued on.
  • VA-TFT displays derived from the English: “vertically aligned”
  • R 1 is -F, -CN, -Cl, -CF 3 or, independently of R 2 , has one of the meanings listed for R 2 ;
  • a 1 is 1,4-phenylene, 1,4-cyclohexylene, pyridine-2,5-diyl, pyrimidine-2,5-diyl, (1, 3) -thiazole-2,5-diyl, (1, 3) -Thiazol-2,4-diyl, where one or more hydrogens can also be substituted by F, (1, 3,4) thiadiazole-2,5-diyl;
  • M 1 is a single bond, -C ⁇ C-, -CH 2 CH 2 -, -O-CO-, -CO-O-, -CO-, -OCH 2 -, -CH 2 0-, -O-CO -O-; and m is zero or one.
  • the ⁇ of the compounds disclosed in this document is not sufficient to ensure satisfactory properties, for example in VA-TFT displays.
  • An object of the present invention was to provide compounds with advantageous properties for use in liquid-crystalline media.
  • -CH 2 F, -CHF 2 , -CF 3 , -OCH 3 , -OCH 2 F, -OCHF 2 or -OCF 3 can be substituted, 1, 4-cyclohexylene, 1, 4-cyclohexenylene or 1, 4-cyclohexadienylene , in which -CH 2 - can be replaced once or twice independently of one another by -O- or -S- such that heteroatoms are not directly adjacent, and which can be substituted once or more by halogen, 1,3-cyclo- butylene or bicyclo [2.2.2] octane,
  • R is hydrogen, an unsubstituted, an alkyl-, alkoxy-, simply substituted by -CF 3 or at least monosubstituted by halogen,
  • Alkenyl or alkynyl radical having 1 to 15 or 2 to 15 carbon atoms, one or more CH2 groups in these radicals each being independently of one another by —O-, -S-, -CO-, -COO-, -OCO - or -OCO-O- can be replaced so that heteroatoms are not directly adjacent, halogen, -CN, -SCN, -NCS, -SF 5 ,
  • n 0, 1, 2 or 3 and L - L each independently of one another are hydrogen, an unsubstituted or an at least mono-substituted alkyl, alkoxy, alkenyl or alkynyl radical having 1 to 15 or 2 to 15 C atoms, one or more CH 2 -Groups can each independently be replaced by -O-, -S-, -CO-, -COO-, -OCO- or -OCO-O- so that heteroatoms are not directly adjacent, halogen, -CN, -SCN , -NCS, -SF 5 , -CF 3 , -OCF 3 , -OCHF 2> -OCH 2 F or - (ZA-) n -R,
  • Another object of the present invention was to provide liquid-crystalline compounds, in particular for use in VA-TFT displays.
  • This object is achieved according to the invention by providing cyclopenta [b] naphthaiine derivatives with a negative ⁇ .
  • the present invention thus relates in particular to cyclopenta [b] naphthalene derivatives of the general formulas (II) to (VI)
  • Cyclohexadienylene in which -CH 2 - can be replaced once or twice independently of one another by -O- or -S- so that heteroatoms are not directly adjacent, and which can be substituted once or more by halogen, 1, 3-cyclo - butylene or bicyclo [2.2.2] octane,
  • R is hydrogen, an unsubstituted, an alkyl, alkoxy, alkenyl or alkynyl radical with 1 to 15 or 2 to 15 carbon atoms which is simply substituted by -CF3 or at least monosubstituted by halogen, one or more CH 2 -Groups can each independently be replaced by -O-, -S-, -CO-, -COO-, -OCO- or -OCO-O- so that heteroatoms are not directly adjacent, halogen, -CN, -SCN , -NCS, -SF 5 , -CF 3 , -OCF3, -OCHF2 or -OCH 2 F,
  • L 2 , L 3 , L 8 each independently of one another are hydrogen, an unsubstituted or at least one halogen-substituted alkyl, alkoxy, alkenyl or alkynyl radical having 1 to 15 or 2 to 15 carbon atoms, with these radicals also one or more CH2 groups independently of one another by -O-,
  • n -R, L 4 , L 6 each independently of one another are hydrogen, an alkyl, alkoxy, alkenyl or alkynyl radical with 1 to 15 or 2 to 15 C atoms which is at least monosubstituted by halogen, one or more CH 2 - also being present in these radicals.
  • Groups can each independently be replaced by -O-, -S-, -CO-, -COO-, -OCO- or -OCO-O- so that heteroatoms are not directly adjacent, halogen, -CN, -SF 5 , -SCN, -NCS, -CF 3 , -OCF 3 , -OCHF 2 or -OCH 2 F, preferably with the proviso that L 4 and L 6 must not be hydrogen at the same time, and
  • n 0, 1, 2 or 3
  • ), (V) and (VI) are preferred, and cyclopenta [b] naphthalene derivatives of the general formulas (II) and (VI) are particularly preferred.
  • the compounds all have a negative ⁇ and are therefore particularly suitable for use in VA TFT displays.
  • the compounds according to the invention preferably have a ⁇ ⁇ -2 and particularly preferably a ⁇ ⁇ -5. They show a very good compatibility with the usual substances used in liquid crystal mixtures for displays.
  • substituents preferably fluorine substituents
  • Naphthalene skeleton and the electronegative atoms in ring B generate a dipole moment perpendicular to the longitudinal axis of the molecule, which can optionally be further strengthened by suitable substituents in the wing units - (ZA-) n -R.
  • the compounds of the formulas (II) to (VI) align with their longitudinal axis perpendicular to the treated or coated glass surface of the display. Preferred as general formulas (II) to (VI)
  • A is preferably, independently of one another, optionally substituted 1,4-phenylene, optionally substituted 1,4-cyclohexylene, in which -CH 2 - can be replaced once or twice by -O-, or optionally substituted 1, 4-cyclohexenylene.
  • A are particularly preferably independent of one another
  • R, L 2 and L 3 in the general formulas (II) to (VI) can each independently of one another be an alkyl radical and / or an alkoxy radical having 1 to 15 carbon atoms, which can be straight-chain or branched. It is preferably straight-chain, has 1, 2, 3, 4, 5, 6 or 7 carbon atoms and is therefore preferably methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyi, methoxy, ethoxy, propoxy, butoxy, pentoxy, Hexoxy or heptoxy.
  • R, L 2 and L 3 can each independently be an alkenyl radical having 2 to 15 carbon atoms, which can be straight-chain or branched. It is preferably straight-chain and has 2 to 7 carbon atoms. Accordingly, it is preferably vinyl, prop-1- or prop-2-enyl, but-1-, 2- or but-3-enyl, Pent-1-, 2-, 3- or Pent-4-enyl, Hex-1-, 2-, 3-, 4- or Hex-5-enyl, Hept-1-, 2-, 3-, 4- , 5- or hept-6-enyl.
  • R, L 2 and L 3 can each independently be an alkyl radical having 1 to 15 carbon atoms, in which one CH 2 group is replaced by -O- and one by -CO-, these preferably being adjacent. Thus, this contains an acyloxy group -CO-O- or an oxycarbonyl group -O-CO-. This is preferably straight-chain and has 2 to 6 carbon atoms.
  • R, L 2 and L 3 can each independently be an alkyl radical having 1 to 15 C atoms or an alkenyl radical having 2 to 15 C atoms which is simply substituted by - CN or -CF 3 , these preferably being straight-chain. The substitution by -CN or -CF 3 is possible in any position.
  • R, L 2 and L 3 can each independently be an alkyl radical in which two or more CH 2 groups are replaced by -O- and / or -CO-O-, which can be straight-chain or branched. It is preferably branched and has 3 to 12 carbon atoms.
  • R, L 2 , L 3 , L 4 and L 6 can each independently be an at least monosubstituted alkyl radical having 1 to 15 carbon atoms or an alkenyl radical having 2 to 15 carbon atoms, these radicals preferably being straight-chain and halogen is preferably -F or -Cl. In the case of multiple substitution, halogen is preferably -F.
  • the resulting residues also include perfluorinated residues such as -CF 3 .
  • the fluorine or chlorine substituent can be in any position, preferably in the ⁇ position.
  • R in the general formulas (II) to (VI) is particularly preferably an alkyl radical, alkoxy radical or alkenyl radical having 1 to 7 or 2 to 7 C atoms.
  • L 2 and L 3 in the general formulas (II) to (VI) are preferably hydrogen, an alkyl radical, alkoxy radical or alkenyl radical having 1 to 7 or 2 to 7 carbon atoms or a halogen, particularly preferably hydrogen
  • Alkoxy radical with 1 to 7 carbon atoms fluorine or chlorine, and in particular fluorine.
  • L 4 and L 6 in the general formulas (II) to (VI) are preferably hydrogen, an at least monosubstituted by halogen
  • L 8 in the general formulas (II) to (VI) is preferably fluorine.
  • Another object of the present invention was to provide connections, in particular for use in mesogenic control media, these control media being used in particular in electro-optical light control elements which are operated at a temperature at which the mesogenic control medium is used. uncontrolled state in the isotropic phase.
  • This object is achieved according to the invention by providing cyclopenta [b] naphthalene derivatives with a positive ⁇ .
  • the present invention thus relates in particular to cyclopenta [b] naphthalene derivatives of the general formulas (VII) to (XI)
  • Cyclopenta [b] naphthalene derivatives of the general formulas (VII) and (XI) are preferred, and cyclopenta [b] naphthalene derivatives of the general formula (VII) are particularly preferred.
  • the compounds of the formulas (VII) to (XI) all have a positive ⁇ .
  • the compounds of the formulas (VII) to (XI) according to the invention preferably have a ⁇ > +10, particularly preferably a ⁇ > +15 and in particular a ⁇ > +20. They show very good compatibility with the usual substances used in mesogenic control media.
  • cyclopenta [b] naphthalene derivatives of the general formula (VII) preferably have the following structural formulas:
  • A is preferably, independently of one another, optionally substituted 1,4-phenylene, optionally substituted 1,4-cyclohexylene, in which -CH 2 - can be replaced once or twice by -O-, or optionally substituted 1,4-cyclohexenylene.
  • A are particularly preferably independent of one another
  • Preferred groups Z in the compounds of the general formulas (VII) to (XI) are each, independently of one another, a single bond, -CF 2 O-,
  • R and L 1 to L 8 in the general formulas (VII) to (XI) can each independently be an alkyl radical and / or an alkoxy radical having 1 to 15 carbon atoms, which can be straight-chain or branched. It is preferably straight-chain, has 1, 2, 3, 4, 5, 6 or 7 carbon atoms and is therefore preferably methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, Hexoxy or heptoxy.
  • R and L 1 to L 8 in the general formulas (VII) to (XI) can each independently be an alkenyl radical having 2 to 15 C atoms, which can be straight-chain or branched. It is preferably straight-chain and has 2 to 7 carbon atoms. Accordingly, it is preferably vinyl, prop-1- or prop-2-enyl, but-1-, 2- or but-3-enyl, pent-1-, 2-, 3- or pent-4-enyl, hex- 1-, 2-, 3-, 4- or hex-5-enyl, hept-1-, 2-, 3-, 4-, 5- or hept-6-enyl.
  • R and L 1 to L 8 in the general formulas (VII) to (XI) can each independently be an alkyl radical having 1 to 15 carbon atoms, in which one CH 2 group is defined by -O- and one by -CO- is replaced, which are preferably adjacent. Thus, this contains an acyloxy group -CO-O- or an oxycarbonyl group -O-CO-. This is preferably straight-chain and has 2 to 6 carbon atoms.
  • R and L 1 to L 8 in the general formulas (VII) to (XI) can each, independently of one another, be an alkyl radical having 1 to 15 C atoms or monkenyl radical having 2 to 15 C atoms which is simply substituted by -CN or -CF 3 , which are preferably straight-chain. The substitution by -CN or -CF 3 is possible in any position.
  • R and L 1 to L 8 in the general formulas (VII) to (XI) can each independently be an alkyl radical in which two or more CH 2 groups have been replaced by -O- and / or -CO-O-, which can be straight-chain or branched. It is preferably branched and has 3 to 12 carbon atoms.
  • R and L 1 to L 8 in the general formulas (VII) to (XI) can each independently be an at least monosubstituted alkyl radical having 1 to 15 carbon atoms or alkenyl radical having 2 to 15 carbon atoms, these radicals are preferably straight-chain and halogen is preferably -F or -CI. In the case of multiple substitution, halogen is preferably -F.
  • the resulting residues also include perfluorinated residues such as -CF 3 .
  • the fluorine or chlorine substituent can be in any position, preferably in the ⁇ position.
  • R in the general formulas (VII) to (XI) is particularly preferably an alkyl radical, alkoxy radical or alkenyl radical having 1 to 7 or 2 to 7 C atoms, in particular an alkyl radical having 1 to 7 C atoms.
  • L 2 and L 3 in the general formulas (VII) to (XI) are preferably, independently of one another, identical or different, hydrogen, halogen, -CN, -SCN, -NCS, -SF 5 , -CF 3 , -CHF 2l -OCF 3 or -OCHF 2 , particularly preferably hydrogen, fluorine, -CF 3 or -OCF 3 .
  • L 2 and / or L 3 is not hydrogen.
  • L 1 and L 4 in the general formulas (VII) to (XI) are preferably, independently of one another, identical or different, hydrogen or fluorine.
  • L 5 and L 6 in the general formulas (VII) to (XI) are preferably hydrogen.
  • the starting materials can also be formed in situ in such a way that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the general formulas (I) to (XI).
  • the examples describe the syntheses of various poly-substituted naphthalene derivatives that are used to construct the five-membered ring.
  • the starting substances can be obtained according to generally accessible literature regulations or are commercially available.
  • the reactions described are also to be regarded as known from the literature.
  • An exemplary synthesis of the structure of the five-membered ring is shown below. The synthesis can be adapted to the desired compounds of the general formulas (I) to (XI) by the choice of suitable starting products.
  • compound c is obtained by reaction with the ⁇ , ⁇ -unsaturated aldehyde b in the presence of lithium diisopropylamide (LDA). This reacts with palladium catalysis in the presence of triethylamine with ring closure to the ketone d. From the ketone d and 1,3-propanedithioI in the presence of BF 3 -diethyl ether receive corresponding Dithian e. This is converted with 1, 3-dibromo-5,5-dimethylhydantoin (DBH) and HF in pyridine to the cyclopenta [b] naphthalene derivative f.
  • DSA lithium diisopropylamide
  • the compounds of the general formulas (I) to (XI) can be used in liquid-crystalline media.
  • the present invention therefore also relates to a liquid-crystalline medium with at least two liquid-crystalline compounds containing at least one compound of the general formulas (I) to (XI).
  • the present invention also relates to liquid-crystalline media comprising, in addition to one or more compounds of the formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), ( IX), (X) and / or (XI) as further constituents 2 to 40, preferably 4 to 30 components.
  • These media particularly preferably contain 7 to 25 components in addition to one or more compounds according to the invention.
  • nematic or nematogenic (monotropic or isotropic) substances are preferably selected from nematic or nematogenic (monotropic or isotropic) substances, in particular substances from the classes of azoxybenzenes, benzylidene anilines, biphenyls, terphenyls, phenyl- or cyclohexylbenzoates, cyclohexanecarboxylic acid phenyl- or -cyclohexyl esters, phenyl- or
  • L and E which may be the same or different, each independently represent a divalent radical from the group consisting of -Phe-, -Cyc- , -Phe-Phe-, -Phe-Cyc-, -Cyc-Cyc-, -Pyr-, -Dio-, -G-Phe- and -G-Cyc- as well as their mirror images formed group, whereby Phe unsubstituted or by fluorine substituted 1, 4-phenylene, cyc trans-1, 4-cyclohexylene or 1, 4-cyclohexylene, pyr pyrimidine-2,5-diyl or pyridine-2,5-diyl, dio 1, 3-dioxane-2, 5-diyl and G signify 2- (trans-1, 4-cyclohexyl) ethyl.
  • one of the residues L and E is Cyc or Phe.
  • E is preferably Cyc, Phe or Phe-Cyc.
  • the media according to the invention preferably contain one or more components selected from the compounds of the formulas (1), (2), (3), (4) and (5), in which L and E are selected from the group Cyc and Phe and simultaneously one or more components selected from the compounds of the formulas (1), (2), (3), (4) and (5), wherein one of the radicals L and E is selected from the group Cyc and Phe and the other radical is selected from the group -Phe-Phe-, -Phe-Cyc-, -Cyc-Cyc-, -G-Phe- and -G-Cyc-, and optionally one or more components selected from the compounds of the formulas (1), (2), (3), (4) and (5), in which the radicals L and E are selected from the group -Phe-Cyc-, -Cyc-Cyc-, - G-Phe-
  • Compounds of the sub-formulas (1a) to (5a) have the meaning indicated and are preferably alkyl, alkenyl, alkoxy or alkoxyalkyl.
  • R "-CN In a further smaller subgroup of the compounds of the formulas (1), (2), (3), (4) and (5), R "-CN; this subgroup is hereinafter referred to as group C and the compounds of this subgroup are correspondingly referred to as partial formulas (1c), (2c), (3c), (4c) and (5c) above.
  • R 1 meaning given for the compounds of the sub-formulas (1a) to (5a) and is preferably alkyl, alkenyl, alkoxy or alkoxyalkyl.
  • the media according to the invention contain and / or (XI) preferably one or more compounds from groups A, B and / or C.
  • the mass fractions of the compounds from these groups in the media according to the invention are:
  • Group A 0 to 90%, preferably 20 to 90%, in particular 30 to 90%
  • Group B 0 to 80%, preferably 10 to 80%, in particular 10 to 70%
  • Group C 0 to 80%, preferably 5 to 80 %, especially 5 to 50%.
  • the media according to the invention preferably contain 1 to 40%, particularly preferably 5 to 30%, of the compounds of the formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X) and / or (XI).
  • the media preferably contain three, four or five compounds according to the invention of the formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), ( X) and / or (XI).
  • the media according to the invention are produced in a conventional manner.
  • the components are dissolved in one another, expediently at elevated temperature.
  • liquid crystalline phases of the present invention are modified so that they can be used in all previously known types of liquid crystal display elements.
  • Such additives are known to the person skilled in the art and are described in detail in the literature (H. Kelker / R. Hatz, Handbook of Liquid Crystals, Verlag Chemie, Weinheim, 1980).
  • pleochroic dyes for producing colored guest-host systems or substances for changing the dielectric anisotropy, the viscosity and / or the orientation of the nematic phases can be added.
  • the compounds of the formulas (II) to (VI) are particularly suitable for use in VA-TFT displays because of their negative ⁇ .
  • the present invention therefore also relates to electro-optical liquid crystal display elements containing a liquid crystalline medium according to the invention.
  • the compounds of the formulas (VII) to (XI) are particularly suitable for use in mesogenic control media, these control media being used in particular in electro-optical light control elements which are operated at a temperature at which the mesogenic control medium is not controlled state is in the isotropic phase.
  • the present invention therefore also relates to electro-optical light control elements, as disclosed for example in DE 102 17 273 A1, which contain an electrode arrangement, at least one element for polarizing the light and a mesogenic control medium, the light control element being operated at a temperature at which the mesogenic control medium is present in the isotropic phase in the uncontrolled state, and which are characterized in that the mesogenic control medium contains one or more compounds of the formulas (VII) to (XI).
  • the starting substances can be obtained according to generally available literature regulations or can be obtained commercially.
  • the reactions described are known from the literature.
  • a solution of 20.0 g (98.5 mmol) of the aldehyde 1 in 100 ml of THF is mixed with 200 ml (100 mmol) of a 0.5 M solution of the zinc compound 2 in THF.
  • the cooling is removed after 30 minutes.
  • the thawed batch is mixed with water, acidified with 1 N HCl solution and with tert. Butylmethyl (MTB) ether extracted. After drying, concentrating and chromatography on silica gel, the hydroxyester 3 is obtained.
  • keto ester 4 9.0 g (29.7 mmol) of keto ester 4 are added to 100 g of polyphosphoric acid at 60 ° C. The temperature is then raised to 120 ° C. for 4 hours. After cooling, the mixture is poured onto ice and tert. Butylmethyl (MTB) ether extracted. After drying, concentration and crystallization, the diketone 5 is obtained.
  • MTB Butylmethyl
  • the batch is heated to 140 ° C. until nitrogen evolution has ended.
  • a solution of 10 g (26.4 mmol) of the protected ketone 9 in 60 ml of dichloromethane is at -75 ° C in a suspension of 30.2 g (105.2 mmol) of 1,3-dibromo-5,5-dimethylhydantoin in 60 ml of dichloromethane and 120 ml of a 65% solution of hydrogen fluoride in pyridine.
  • the mixture is slowly heated to 0 ° C. for 3 hours and added to 1500 ml of an ice-cooled 2N sodium hydroxide solution, to which 120 ml of a 39% sodium hydrogen sulfite solution have been added.
  • the pH is adjusted to 8 and the aqueous phase is extracted with methylene chloride. After drying, concentration and chromatography on silica gel, the fluorinated ester 10 is obtained.
  • the fluorinated ester 10 is ring-closed to the compound 11 as described in Example 1.
  • Example 5 The reduction of the compound 11 to the alcohol 13 and the subsequent elimination of water to the dihydronaphthalene derivative 14 are carried out as described in Example 2.
  • Example 5 The reduction of the compound 11 to the alcohol 13 and the subsequent elimination of water to the dihydronaphthalene derivative 14 are carried out as described in Example 2.
  • a solution of 9 g (34.2 mmol) of the dihydronaphthalene derivative 14 in 50 ml of THF is slowly added to a suspension of 4.5 g (40.1 mmol) of potassium tert-butoxide in 50 ml of THF and then overnight Reflux heated.
  • the cooled mixture is diluted with water and extracted with diethyl ether. After drying, concentrating and chromatography on silica gel, the naphthalene 15 is obtained.
  • the hydroxyester 3 is reacted in dimethylformamide (DMF) at 120 ° C for four hours in the presence of potassium carbonate with benzyl bromide. After cooling, the mixture is poured onto ice water and tert. Butylmethyl (MTB) ether extracted. After drying, concentration and crystallization, the ester 25 is obtained.
  • DMF dimethylformamide
  • MTB Butylmethyl
  • the ether 27 dissolved in THF is reacted on palladium / carbon catalyst in a hydrogen atmosphere. After concentration and chromatography on silica gel, the hydroxy compound 28 is obtained.
  • the ketone 29 is reacted in methanol at 0 to 20 ° C for four hours with iodobenzene diacetate and KOH.
  • the hydroxyketone 30 is obtained.
  • the fluorinated hydroxy compound 32 is mixed with pyridine and POCI 3 with ice cooling. Then alcohol is added. The Reaction takes four hours at 60 ° C. After cooling, the mixture is poured onto ice water and tert. Butylmethyl (MTB) ether extracted. After drying, concentration and crystallization, the unsaturated fluorinated compound 33 is obtained.
  • MTB Butylmethyl
  • the corresponding Grignard compound is prepared from 48.0 g (200 mmol) of the aromatic 34, 4.8 g (200 mmol) of magnesium and 200 ml of toluene / THF (4: 1). 22.5 g (100 mmol) of zinc bromide are then introduced. After 1 hour, 57.6 g (200 mmol) of the aldehyde 35 in 50 ml of solvent are added. After a further 2 hours, the batch is mixed with water and acidified with dil. HCl solution. The aqueous phase is extracted three times with MTB ether. After drying, concentration and chromatography, 60.4 g of the ester 36 are obtained.
  • a suspension of 18.0 g (136 mmol) of aluminum chloride in 50 ml of dichloromethane is mixed with a solution of the acid chloride 38 in 50 ml of dichloromethane at -25 ° C.
  • the batch is kept at a temperature below -12 ° C. until complete conversion (TLC).
  • the reaction is then stopped by carefully adding water (50 ml).
  • the resulting solid is brought into solution using an HCl solution.
  • the aqueous phase is extracted twice with dichloromethane, the organic Phase dried and concentrated. After chromatography, 30.2 g of diketone 39 are obtained.
  • cyclopenta [b] naphthalene derivative 46 6.0 g (14.1 mmol) of the cyclopenta [b] naphthalene derivative 46 are dissolved in 50 ml of dichloromethane, with 2.4 ml (16.0 mmol) of 1, 8-diazabicyclo [5.4.0] - undec-7- en (DBU) are added and the mixture is stirred at room temperature until the starting material is completely converted. The mixture is washed with water and saturated sodium chloride solution, concentrated and chromatographed. The cyclopenta [b] naphthalene derivative 47 is isolated.
  • DBU 1, 8-diazabicyclo [5.4.0] - undec-7- en
  • ⁇ n and ⁇ values of the compound according to the invention were obtained by extrapolation from liquid-crystalline mixtures, which are 5% from the compound according to the invention and 95% from one of the two commercially available liquid crystal mixtures ZLI 4792 and ZLI 2857 (Merck, Darmstadt) passed.
  • a solution of 20.0 g (62.1 mmol) of naphthalene 41 in 100 ml of diethyl ether is mixed at -75 ° C with 38.0 ml of a t7-butyllithium solution in ⁇ -hexane and stirred for 1 hour.
  • 11.2 g (62.1 mmol) of the aldehyde 49 in 50 ml of diethyl ether are then added and the mixture is stirred overnight.
  • the batch is mixed with water.
  • the aqueous phase is extracted with diethyl ether, the organic phase is dried and concentrated. After chromatography, 21.2 g of the allyl alcohol 50 are obtained.
PCT/EP2003/008285 2002-08-26 2003-07-28 Cyclopenta[b]naphthalinderivate WO2004020375A1 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DE50312532T DE50312532D1 (de) 2002-08-26 2003-07-28 CYCLOPENTA iB NAPHTHALINDERIVATE
EP03790821A EP1532090B1 (de) 2002-08-26 2003-07-28 Cyclopenta ¬b naphthalinderivate
AU2003258538A AU2003258538A1 (en) 2002-08-26 2003-07-28 Cyclopenta(b)naphthalene derivatives
KR1020057003174A KR101048559B1 (ko) 2002-08-26 2003-07-28 사이클로펜타[b]나프탈렌 유도체
AT03790821T ATE461166T1 (de) 2002-08-26 2003-07-28 Cyclopenta [b]naphthalinderivate
JP2004569707A JP4722490B2 (ja) 2002-08-26 2003-07-28 シクロペンタ[b]ナフタレン誘導体
US10/524,846 US7291366B2 (en) 2002-08-26 2003-07-28 Cyclopenta[b]naphthalene derivatives
US11/931,711 US7612243B2 (en) 2002-08-26 2007-10-31 Cyclopenta[b]naphthalene derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10238999.3 2002-08-26
DE10238999A DE10238999A1 (de) 2002-08-26 2002-08-26 Cyclopenta(b)naphthalinderivate
DE10324843.9 2003-06-02
DE2003124843 DE10324843A1 (de) 2003-06-02 2003-06-02 Cyclopenta [b] naphthalinderivate

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10524846 A-371-Of-International 2003-07-28
US11/931,711 Division US7612243B2 (en) 2002-08-26 2007-10-31 Cyclopenta[b]naphthalene derivatives

Publications (1)

Publication Number Publication Date
WO2004020375A1 true WO2004020375A1 (de) 2004-03-11

Family

ID=31979454

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/008285 WO2004020375A1 (de) 2002-08-26 2003-07-28 Cyclopenta[b]naphthalinderivate

Country Status (9)

Country Link
US (2) US7291366B2 (US07291366-20071106-C00087.png)
EP (1) EP1532090B1 (US07291366-20071106-C00087.png)
JP (1) JP4722490B2 (US07291366-20071106-C00087.png)
KR (1) KR101048559B1 (US07291366-20071106-C00087.png)
AT (1) ATE461166T1 (US07291366-20071106-C00087.png)
AU (1) AU2003258538A1 (US07291366-20071106-C00087.png)
DE (1) DE50312532D1 (US07291366-20071106-C00087.png)
TW (1) TWI304836B (US07291366-20071106-C00087.png)
WO (1) WO2004020375A1 (US07291366-20071106-C00087.png)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021682A1 (de) * 2003-08-22 2005-03-10 Merck Patent Gmbh Cyclopenta[a]naphthalinderivate
WO2006108713A2 (de) * 2005-04-14 2006-10-19 Schering Aktiengesellschaft 1-amino-1, 2, 3, 4-tetrahydro-naphtalin-2-ol derivate als entzündungshemmer
WO2007009636A1 (de) * 2005-07-20 2007-01-25 Merck Patent Gmbh S-indacen- und indeno[5,6-d][1,3]dioxol-derivate und deren verwendung als komponente flüssigkristalliner mischungen
DE102008027972A1 (de) 2007-07-02 2009-01-08 Merck Patent Gmbh Naphthofuranderivate
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7659297B2 (en) 2003-10-08 2010-02-09 Bayer Schering Pharma, AG Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7880042B2 (en) 2006-03-15 2011-02-01 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, methods for the production thereof, and the use thereof as antiphlogistics
US8097627B2 (en) 2004-04-05 2012-01-17 Bayer Pharma AG Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101048559B1 (ko) * 2002-08-26 2011-07-11 메르크 파텐트 게엠베하 사이클로펜타[b]나프탈렌 유도체
US20060084652A1 (en) * 2004-09-09 2006-04-20 Stefan Baeurle Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20060229305A1 (en) * 2005-03-22 2006-10-12 Markus Berger Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20070015761A1 (en) * 2005-04-14 2007-01-18 Anne Mengel Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
JP5311009B2 (ja) * 2008-08-14 2013-10-09 日本ゼオン株式会社 含水素フルオロオレフィン化合物の製造方法
US9133234B2 (en) 2012-05-16 2015-09-15 Kay M. Brummond Functionalized naphthalene fluorophores
KR102511837B1 (ko) 2016-01-20 2023-03-20 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
CN110105165A (zh) * 2019-06-12 2019-08-09 黑龙江省科学院石油化学研究院 一种高纯度1,4-二溴萘的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06263663A (ja) * 1993-03-10 1994-09-20 Asahi Glass Co Ltd 含フッ素インダン環誘導体化合物およびそれを含有する液晶組成物
DE4434974A1 (de) * 1994-09-30 1996-04-04 Hoechst Ag Tricyclische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
WO1998046547A1 (en) * 1997-04-15 1998-10-22 Montell Technology Company B.V. Process for preparing 2-aryl-substituted indenes
WO2002046330A1 (de) * 2000-12-06 2002-06-13 Merck Patent Gmbh Flüssigkristallines medium
EP1223209A1 (de) * 2001-01-11 2002-07-17 Clariant International Ltd. Fluorierte Fluorene und ihre Verwendung in Flüssigkristallmischungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH115799A (ja) * 1997-06-18 1999-01-12 Idemitsu Petrochem Co Ltd 有機ハフニウム化合物、オレフィン重合用触媒およびオレフィン系重合体の製造方法
DE10110307A1 (de) * 2001-03-03 2002-09-05 Nematel Dr Rudolf Eidenschink Tricyclische Verbindungen
AU2002342821A1 (en) * 2001-05-16 2002-11-25 Merck Patent Gmbh Electro-optic light control element, display and medium
DE10145779B4 (de) * 2001-09-17 2012-11-15 Merck Patent Gmbh Fluorierte Cyclopenta[b]naphthaline und ihre Verwendung in Flüssigkristallmischungen
KR101048559B1 (ko) * 2002-08-26 2011-07-11 메르크 파텐트 게엠베하 사이클로펜타[b]나프탈렌 유도체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06263663A (ja) * 1993-03-10 1994-09-20 Asahi Glass Co Ltd 含フッ素インダン環誘導体化合物およびそれを含有する液晶組成物
DE4434974A1 (de) * 1994-09-30 1996-04-04 Hoechst Ag Tricyclische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
WO1998046547A1 (en) * 1997-04-15 1998-10-22 Montell Technology Company B.V. Process for preparing 2-aryl-substituted indenes
WO2002046330A1 (de) * 2000-12-06 2002-06-13 Merck Patent Gmbh Flüssigkristallines medium
EP1223209A1 (de) * 2001-01-11 2002-07-17 Clariant International Ltd. Fluorierte Fluorene und ihre Verwendung in Flüssigkristallmischungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 122, no. 16, 17 April 1995, Columbus, Ohio, US; abstract no. 201408, YOKOKOJI, OSAMU ET AL: "Fluorine-containing indane derivatives and liquid crystal compositions containing same" XP002248134 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575785B2 (en) 2003-08-22 2009-08-18 Merck Patent Gmbh Cyclopenta[a]naphthaline derivatives
WO2005021682A1 (de) * 2003-08-22 2005-03-10 Merck Patent Gmbh Cyclopenta[a]naphthalinderivate
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7659297B2 (en) 2003-10-08 2010-02-09 Bayer Schering Pharma, AG Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US8097627B2 (en) 2004-04-05 2012-01-17 Bayer Pharma AG Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
WO2006108713A3 (de) * 2005-04-14 2006-12-14 Schering Ag 1-amino-1, 2, 3, 4-tetrahydro-naphtalin-2-ol derivate als entzündungshemmer
WO2006108713A2 (de) * 2005-04-14 2006-10-19 Schering Aktiengesellschaft 1-amino-1, 2, 3, 4-tetrahydro-naphtalin-2-ol derivate als entzündungshemmer
WO2007009636A1 (de) * 2005-07-20 2007-01-25 Merck Patent Gmbh S-indacen- und indeno[5,6-d][1,3]dioxol-derivate und deren verwendung als komponente flüssigkristalliner mischungen
JP2009505951A (ja) * 2005-07-20 2009-02-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング s−インダセンおよびインデノ[5,6−d]−1,3−ジオキソール誘導体類、および液晶混合物の成分としてのそれの使用
US7922934B2 (en) 2005-07-20 2011-04-12 Merck Patent Gesellschaft Mit Beschrankter Haftung s-Indacene and indeno[5,6-d][1,3]dioxol-derivatives and use thereof as components of liquid-crystal mixtures
KR101287242B1 (ko) 2005-07-20 2013-07-17 메르크 파텐트 게엠베하 S-인다센 및 인데노[5,6-d]-1,3-다이옥솔 유도체, 및 액정 혼합물의 성분으로서의 그의 용도
US7880042B2 (en) 2006-03-15 2011-02-01 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, methods for the production thereof, and the use thereof as antiphlogistics
DE102008027972A1 (de) 2007-07-02 2009-01-08 Merck Patent Gmbh Naphthofuranderivate
DE102008027972B4 (de) 2007-07-02 2023-06-22 Merck Patent Gmbh Naphthofuranderivate

Also Published As

Publication number Publication date
EP1532090A1 (de) 2005-05-25
KR101048559B1 (ko) 2011-07-11
JP2005537334A (ja) 2005-12-08
JP4722490B2 (ja) 2011-07-13
DE50312532D1 (de) 2010-04-29
US7612243B2 (en) 2009-11-03
US20080058537A1 (en) 2008-03-06
KR20050038637A (ko) 2005-04-27
TW200407415A (en) 2004-05-16
TWI304836B (en) 2009-01-01
ATE461166T1 (de) 2010-04-15
US7291366B2 (en) 2007-11-06
EP1532090B1 (de) 2010-03-17
AU2003258538A1 (en) 2004-03-19
US20060165915A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
EP1742931B1 (de) Dibenzofuran-, dibenzothiophen- und fluorenderivate als komponenten in flüssigkristallmischungen
EP3085753B1 (de) Fluorierte dibenzofuran- und dibenzothiophenderivate
EP1409441B1 (de) Indanverbindungen mit negativer dielektrischer anisotropie
DE10157674B4 (de) Alkenylverbindungen mit negativer DK-Anisotropie und flüssigkristallines Medium
DE102015004271A1 (de) 4,6-Difluor-dibenzothiophen-Derivate
EP1532090B1 (de) Cyclopenta ¬b naphthalinderivate
EP1926798B1 (de) Cyclobutan- und spiro[3.3]heptanverbindungen
DE102004037387B4 (de) Cyclopenta[a]naphthalinderivate
EP1852429B1 (de) Hexahydro-dibenzofuranderivate
WO2019007821A1 (de) Thioether-derivate des dibenzothiophens und des dibenzofurans
WO2006012965A1 (de) Difluorsubstitierte heterocyclische verbindungen und deren verwendung als komponenten in flüssigkristallinen medien
DE10214938A1 (de) Fluorierte Indene und 1,7-Dihydroindacene mit negativem delta epsilon
DE112018005139T5 (de) Dibenzofuran- und Dibenzothiophenderivate
EP1741000B1 (de) As-indacenderivate mit negativer dielektrischer anisotropie
DE19933175A1 (de) Fluorcyclohexan-Derivate und flüssigkristallines Medium
EP1904470B1 (de) S-indacen- und indeno[5,6-d][1,3]dioxol-derivate und deren verwendung als komponente flüssigkristalliner mischungen
DE10238999A1 (de) Cyclopenta(b)naphthalinderivate
DE102005016985A1 (de) as-Indacenderivate
DE102006038304A1 (de) Cyclobutan- und Spiro[3.3]heptanverbindungen
EP1174405A2 (de) Dialkinverbindungen
DE102008027972B4 (de) Naphthofuranderivate
EP2212308B1 (de) Benzo[f]chromen- und pyrano[3,2-f]chromen-derivate zur anwendung in flüssigkristallinen medien
DE10324843A1 (de) Cyclopenta [b] naphthalinderivate
DE10117559A1 (de) 2,4'-substituierte 6-Cyclohexyl-trans-Dekaline
WO2018100019A1 (de) Thioether-verbindungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003790821

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006165915

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10524846

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020057003174

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004569707

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1020057003174

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003790821

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10524846

Country of ref document: US